ArticleBMC medical imaging2025
Integrating clinical features with
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAccurate determination of H3 K27M mutation status is critical for prognosis evaluation and treatment planning in brainstem gliomas (BSGs). We developed a clinical-radiomics model integrating 11C-methionine (11C-MET) positron emission tomography (PET), magnetic resonance imaging (MRI), and clinical features for non-invasive, preoperative prediction of H3 K27M mutation status in BSGs.
methodsThis retrospective study included 77 patients with newly diagnosed BSG who underwent preoperative 11C-MET PET imaging and MRI. Among them, 53 had a histologically confirmed H3 K27M mutation. Patients were randomly divided into training (n = 55) and test (n = 22) cohorts. Clinical variables significantly associated with H3 K27M mutation status were used to construct a clinical model using the extreme gradient boosting (XGBoost) algorithm. Radiomics features were extracted separately from PET and MRI images to construct individual and combined models. A clinical-radiomics integrated model was then developed by combining clinical features and the radiomics model with the best predictive performance. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis (DCA).
resultsThe clinical model achieved AUCs of 0.795 and 0.790 in the training and test cohorts, respectively. The combined PET-MRI radiomics model outperformed individual PET or MRI model, with AUCs of 0.876 and 0.848 in the training and test cohorts, respectively. The clinical-radiomics integrated model achieved the highest performance with AUCs of 0.886 in the training cohort and 0.876 in the test cohort. The calibration curve showed good agreement between predicted and actual outcomes, and DCA demonstrated a superior net clinical benefit of the integrated model.
conclusionsRadiomics analysis based on 11C-MET PET and MRI can effectively predict H3 K27M mutation status in BSGs. Incorporating clinical features further enhances predictive performance, supporting its use in non-invasive, preoperative molecular diagnosis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.